Logo Kérwá
 

CRISPR-Cas technology, the tool of the future

dc.creatorEsquivel Álvarez, Alejandro
dc.creatorQuesada Morales, Elías
dc.creatorVillega Calero, María Paz
dc.creatorMatarrita Brenes, Daniela
dc.creatorRojas Salas, María Fernanda
dc.creatorMadrigal Redondo, German
dc.creatorChavarría Rojas, Marianela
dc.creatorBaltodano Viales, Eleaneth
dc.date.accessioned2024-07-01T15:28:35Z
dc.date.available2024-07-01T15:28:35Z
dc.date.issued2022-03-02
dc.description.abstractThe CRISPR-Cas system discovered in the eighties consists of a series of RNA proteins that signal and messengers of the immune system in prokaryotic organisms to protect against invading antigens of various sources. After the CRISPR-Cas discovery, many research advances were made in the following decades regarding knowledge, techniques, and applications. This showed the system could edit the DNA in an exact and specific manner, which made it very promising to exploit it in various fields, such as the therapeutic field. New therapies of various diseases, industrial applications, food manufacturing, among others, make its impact quite relevant. The following review will focus on the fundamental understanding and implications of CRISPR-Cas techniques has with an ethical and legal view. In addition, to explore some of the applications present and future in the healthcare department, some methods of drug delivery in gene therapy, and new research that is being developed with the CRISPR-Cas technology.es
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones Farmacéuticas (INIFAR)es
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Farmaciaes
dc.identifier.citationhttps://ejbio.org/index.php/ejbio/article/view/332
dc.identifier.doihttps://doi.org/10.24018/ejbio.2022.3.2.332
dc.identifier.issn2684-5199
dc.identifier.urihttps://hdl.handle.net/10669/91673
dc.language.isoeng
dc.rightsacceso abiertoes
dc.sourceEuropean Journal of Biology & Biotechnology, 3(2), 1-9es
dc.subjectCRISPR-Cases
dc.subjectDNAes
dc.subjectGenees
dc.subjectPharmacyes
dc.subjectRNAes
dc.subjectTHERAPYes
dc.titleCRISPR-Cas technology, the tool of the futurees
dc.typeartículo originales

Files

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
3.5 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections